Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sophiris Bio Inc SPHS

Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is a genetically modified recombinant protein which is selectively activated by enzymatically active prostate-specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. Geographically all the operations of the company are functioned in the United States.


EXPM:SPHS - Post by User

Bullboard Posts
Comment by rythmanon May 01, 2013 3:12pm
69 Views
Post# 21325537

RE: RE: RE: RE: Is it the end

RE: RE: RE: RE: Is it the end

If it was so simple, call the IR and get all the latest...latest what, they don't know anymore than we do. In fact, even if they did know something more they couldn't release it until it is published. So what's the point of talking to them. It's a financing overhang without a solution, and the question is where do we get the funds for the next study, if in fact there will be one. I just want to know. I'm pretty sure everyone else does as well. What do you know that we don't. Your last post, said wait another month, do you know something is coming, and how do you know it? Rythman

Bullboard Posts